Table 1.
Factors | No. (%) |
---|---|
Total patients | 291 |
Median age at first surgery, y | 40 |
Median age at first MRI, y | 39 |
Male | 158 (54%) |
Histologic classification, WHO 2007 | |
Oligodendroglioma | 137 (47%) |
Astrocytoma | 61 (21%) |
Oligoastrocytoma | 74 (25%) |
NOS | 19 (7%) |
Integrated classification, WHO 2016 | |
Oligodendroglioma, IDH-mutated, 1p/19q codeleted | 92 (36%) |
Diffuse astrocytoma, IDH-mutated, 1p/19q intact | 109 (43%) |
Diffuse astrocytoma, IDH wild-type | 53 (21%) |
Not tested | 37 (NA) |
Tumor location | |
Temporal and insula | 74 (25%) |
Non-temporal (frontal, parietal, and occipital lobes) | 196 (67%) |
Other (midline and deep structures, brainstem, and cerebellum) | 21 (7%) |
Patients with preoperative seizures | 197 (68%) |
With postoperative seizures | 143 (73%) |
Without postoperative seizures | 54 (27%) |
Patients with postoperative seizures | 183 (63%) |
With preoperative seizures | 143 (78%) |
Without preoperative seizures | 40 (22%) |
Patients with intractable seizures | 120 (41%) |
Seizure types | |
Generalized onset | 81 (41%) |
Focal onset | 79 (40%) |
Focal onset with secondary generalization | 23 (12%) |
Unclear semiology | 14 (7%) |
Types of surgery | |
Gross total resection/lobectomy | 41 (14%) |
Subtotal resection | 128 (44%) |
Biopsy | 120 (42%) |
Undetermined | 2 (NA) |
Abbreviations: IDH, isocitrate dehydrogenase; NA, not applicable; NOS, not otherwise specified; WHO, World Health Organization.